Hong Kong
China
HKU Business School, The University of Hong Kong
New Drugs, Mandatory Information Disclosure, Information Diffusion, Divestment, Welfare Analysis
Firm Initial Conditions, R&D Competence, Innovation, Diversification, Firm Growth
Disclosure; Voluntary Nondisclosure, Redacted Information, Signaling, Proprietary Information, Confidential Treatment Order
Medical devices, technology spillovers, cumulative innovation, 510(k) premarket notification
Mandatory disclosure, Proprietary information, Confidential treatment, Material contract redaction, Acquisition likelihood, Merger surplus